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Robust activation of the innate immune re-
sponse is essential for immediate defense against 
infection as well as for the generation of a long-
lasting adaptive immunity against pathogens. 
However, if it is not terminated properly, the 
response can be harmful to the host, leading to 
the pathological manifestations of acute and 
chronic inflammatory disorders. Thus, it is not 
surprising that nature utilizes numerous and 
sometimes redundant molecular mechanisms 
to keep inflammation in check. Decades of in-
tense study have uncovered multiple layers of 
innate immune regulation, from soluble recep-
tors to inducible intracellular protein regulators 
(Liew et al., 2005). However, the full picture of 
how innate immune responses are modulated 
to avoid overreaction has yet to be painted.
MicroRNAs (miRNAs), a family of small 
noncoding RNAs, have recently emerged 
as powerful posttranscriptional regulators of 
various biological processes from cell fate de-
termination to signaling events (Ambros, 2004; 
Bartel, 2004). A growing body of evidence sug-
gests that the development and function of cells 
in the immune system is particularly subject 
to regulation by miRNAs (Baltimore et al., 
2008; Tsitsiou and Lindsay, 2009). A few years 
ago, we postulated that miRNAs might com-
prise a novel layer of regulation of the innate 
immune response and performed a systematic 
effort to identify miRNAs that might be in-
volved in the mammalian response to microbial 
infection (Taganov et al., 2006). We identified 
three miRNA genes (miR-146a, miR-132, 
and miR-155) whose expression is sharply up-
regulated in response to LPS, and this list was 
later expanded further to include miR-9, miR-21, 
and miR-147 through the work of others 
(Bazzoni et al., 2009; Liu et al., 2009; Sheedy 
et al., 2010).
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Excessive or inappropriate activation of the immune system can be deleterious to the 
organism, warranting multiple molecular mechanisms to control and properly terminate 
immune responses. MicroRNAs (miRNAs), 22-nt-long noncoding RNAs, have recently 
emerged as key posttranscriptional regulators, controlling diverse biological processes, 
including responses to non-self. In this study, we examine the biological role of miR-146a 
using genetically engineered mice and show that targeted deletion of this gene,  
whose expression is strongly up-regulated after immune cell maturation and/or activation, 
results in several immune defects. Collectively, our findings suggest that miR-146a  
plays a key role as a molecular brake on inflammation, myeloid cell proliferation, and 
oncogenic transformation.
© 2011 Boldin et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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result, many die prematurely. Mechanistically, autoimmunity 
in the KO mice correlated with the loss of peripheral T cell 
tolerance. Using a combination of gain and loss of function 
approaches, we have confirmed TRAF6 and IRAK1 genes as 
bona fide miR-146a targets, whose derepression in miR-146a 
KO mice might account for some of the observed immune 
phenotypes. In addition, we found that miR-146a seems 
to play a role in the control of immune cell proliferation; 
aging miR-146a–null mice display an excessive production 
of myeloid cells and develop frank tumors in their secondary 
lymphoid organs, suggesting that miR-146a can function as a 
tumor suppressor in the context of the immune system. 
Collectively, our results clearly establish miR-146a as an im-
portant negative regulator of inflammation, myeloid cell pro-
liferation, and cancer.
RESULTS
miR-146a is up-regulated in immune cells in response  
to activation and/or upon maturation
To establish the functional role of miR-146a in the immune 
system, we first surveyed its expression in mouse hematopoi-
etic tissues. Expression of mature miR-146a was found to be 
relatively high in dendritic cells, thioglycollate-elicited mac-
rophages and granulocytes, and peripheral B and T cells but 
low in the corresponding precursor populations and non-
immune tissues (Fig. 1 A). This suggests that miR-146a might 
be involved in the development and homeostasis of both my-
eloid and lymphoid cell lineages. Moreover, consistent with 
our and others’ previous findings (Taganov et al., 2006; Brown 
et al., 2007; Landgraf et al., 2007), we have also observed an 
miR-146a is a member of the miR-146 miRNA family, 
consisting of two evolutionary conserved miRNA genes: 
miR-146a and miR-146b. In people, these loci are located on 
separate chromosomes, in quite unrelated sequence contexts, 
but differ in their mature sequence only by 2 nt at the 3 end. 
Previously, we have shown that both genes respond to LPS in 
human monocytes, but only miR-146a is processed to a ma-
ture form, and determined that induction of expression of 
miR-146a is NF-B dependent (Taganov et al., 2006). Based 
on our in vitro results, we proposed a model suggesting 
that miR-146a acts as a negative feedback regulator of the 
innate immune response by targeting two adapter proteins, 
TRAF6 (TNF receptor–associated factor 6) and IRAK1 
(IL-1 receptor-associated kinase 1), that are crucial for pro-
inflammatory signaling.
To test this notion experimentally and to further under-
stand the biological role of miR-146a, we have created mutant 
mice with a targeted deletion of this gene. We have found that 
in mice, miR-146a is expressed predominantly in immune tis-
sues, and its expression can be induced in immune cells upon 
cell maturation and/or activation. Ablation of miR-146a ex-
pression in mice results in several immune-related pheno-
types, correlating well with its localization of expression. Lack 
of miR-146a expression results in hyperresponsiveness of 
macrophages to bacterial LPSs and leads to an exaggerated 
inflammatory response in endotoxin-challenged mice. In 
contrast, overexpression of miR-146a in monocytes has the 
opposite effect. Later in life, miR-146a–null mice develop a 
spontaneous autoimmune disorder, characterized by spleno-
megaly, lymphadenopathy, and multiorgan inflammation; as a 
Figure 1. Profile of miR-146a gene expression in normal mouse tissues and abrogation of its expression in miR-146a/ mice. (A) qRT-PCR 
analysis of mature miR-146a expression in various mouse tissues (BALB/c strain) and purified hematopoietic cells. Data are the mean of three mouse 
samples, and miR-146a expression from different tissues was normalized by U6 snRNA level. PMN, polymorphonuclear leukocyte; M, macrophages; 
BM-Gr1+, purified Gr1+ cells from BM; BM-CD19+, purified CD19+ BM cells; SP-CD4+, purified CD4+ splenocytes; SP-CD19+, purified CD19+ splenocytes; 
PeC PMN, thioglycollate-elicited neutrophils lysed immediately after isolation or after being cultured in vitro for 3 h; PeC Mac, thioglycollate-elicited 
macrophages cultured in vitro for 16 h with or without 20 ng/ml LPS; SP DC, CD11c+MHCII+ splenic dendritic cells; BMpDC, BM-derived Flt3L-differenti-
ated B220+Ly6C+PDCA1+CD11b plasmacytoid dendritic cells; BMpDC 24 h CpG, BMpDCs stimulated with 5 µg/ml CpG for 24 h. Expression level of miR-
146a in thymocytes was set arbitrarily to 1. Data are represented as mean ± SD. (B) Northern Blot analysis of miR-146a expression in splenocytes isolated 
from WT, miR-146a+/ (HET), and miR-146a/ (KO) mice on two different genetic backgrounds, as indicated. Membrane was probed with DNA oligo-
nucleotide complementary to mature miR-146a and then reprobed with sno234 probe to control for loading (bottom).
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miR-146a–null macrophages are hyperresponsive to LPS
Tissue macrophages are considered a primary source of pro-
inflammatory cytokine production. Therefore, to explain the 
LPS hyperresponsiveness observed in miR-146a mutant mice, 
we examined the effect of miR-146a deletion on primary 
macrophage function. We determined the levels of secreted 
proinflammatory cytokines by miR-146a/ BM-derived 
macrophages (BMDMs) after LPS stimulation by ELISA and 
found a significant increase in the level of production of TNF, 
IL-6, and IL-1 proteins in comparison with WT cells (Fig. 2, D 
and E; and Fig. S2 E). miR-146a–null BMDMs also produced 
more nitric oxide in response to endotoxin than WT cells 
(unpublished data).
Monocytes overexpressing miR-146a show a dampened 
inflammatory response
A role for miR-146a in macrophage activation and control of 
proinflammatory cytokine production was further supported 
by miR-146a overexpression experiments in human mono-
cytic THP-1 cells. To create cells with ectopic expression of 
miR-146a (THP1/146), we transduced THP-1 cells with a len-
tivirus carrying a miR-146a expression cassette under control 
of the ubiquitin promoter (Fig. S3 A). As a control, we also 
generated a THP-1 line expressing a scrambled miR-146a se-
quence (THP1/SCR) using the same lentiviral vector. Analy-
sis of miR-146a expression in THP1/146 cells by qRT-PCR 
revealed a 10-fold increase in mature miR-146a levels in 
comparison with THP1/SCR control cells (Fig. S3 B), which 
is about the level of miR-146a up-regulation seen in THP-1 
cells after LPS challenge (Taganov et al., 2006). In striking 
contrast to primary miR-146a KO macrophages, stimulation 
of THP1/146 cells with LPS resulted in significantly attenu-
ated production of proinflammatory cytokines, including 
TNF, IL-6, and IL-12, in comparison with THP1/SCR cells 
(Fig. 3, A and B; and Fig. S3 C). These results are in agreement 
with previous studies showing that overexpression of miR-146a 
in cell lines results in the dampening of proinflammatory re-
sponse (Perry et al., 2008; Nahid et al., 2009). Collectively, our 
findings support the proposition (Taganov et al., 2006) that 
miR-146a plays a negative role in the control of inflamma-
tion in primary macrophages.
TRAF6 and IRAK1 are bona fide targets of miR-146a
To understand the molecular mechanism by which miR-146a 
can regulate macrophage function, we performed expression 
profiling of primary macrophages derived from WT and KO 
animals using Affymetrix microarrays. miRNAs are believed 
to regulate the expression of hundreds of gene targets by 
binding to sequences within the 3 untranslated regions 
(UTRs) of target messenger RNAs (mRNAs) that are com-
plementary to nucleotides 2–8 (seed sequence) of the miRNA. 
The degree of the target regulation is usually very modest and 
correlates with the level of destabilization of the mRNA (Baek 
et al., 2008). Analysis of the expression data from miR-146a–null 
BMDMs by the Sylamer algorithm (van Dongen et al., 2008) 
did not reveal global derepression of miR-146a seed-matched 
increase in miR-146a expression in mouse primary macro-
phages, dendritic cells, and neutrophils in response to Toll-like 
receptor (TLR) agonists (Fig. 1 A and not depicted), suggest-
ing that this miRNA may play an important role in the re-
sponse of myeloid cells to infection.
Generation of mice with targeted deletion  
of miR-146a gene
To test experimentally the biological role of miR-146a in the 
immune system, we have created mutant mice bearing a tar-
geted deletion of the miR-146a gene. The miR-146a locus is 
situated on mouse chromosome 11, and its precursor is tran-
scribed from an independent transcriptional unit with its own 
promoter. Therefore, our KO strategy simply called for the re-
moval of an 300-nt-long genomic fragment, containing the 
miR-146a precursor sequence, and replacement of it with a 
single loxP sequence (Fig. S1, A and B). The absence of miR-
146a expression in miR-146a/ mice was confirmed in several 
hematopoietic tissues by Northern blotting and quantitative 
RT-PCR (qRT-PCR; Fig. 1 B and Fig. S1 C). The high ho-
mology of miR-146a and miR-146b has made it difficult to 
determine their individual levels. With miR-146a gone, we 
examined miR-146b levels, and interestingly, we were able to 
detect a low level of expression of mature miR-146b in some 
of the miR-146a KO tissues tested (unpublished data). Future 
studies will be required to determine the exact profile of 
miR-146b expression in mouse tissues, but it seems likely that 
expression of miR-146b is not masking phenotypes caused 
by the miR-146a KO, at least in most immune cells.
We have independently created miR-146a–null alleles in 
the context of two mouse genetic backgrounds, pure C57BL/6 
(hereafter called B6/miR-146a/) and mixed C57BL/6 × 129/
sv (hereafter called 129.B6/miR-146a/). Both KO lines were 
born at the expected Mendelian ratios to their littermates, 
were fertile, displayed no gross morphological abnormalities 
after birth, and produced very similar phenotypes later in life. 
However, certain nuances caused by the differences in ge-
netic background were noted and will be discussed in Aging 
miR-146a–null mice develop autoimmune disorder.
miR-146a–null mice are hypersensitive to LPS
Because our previous findings suggested a negative role for 
miR-146a in control of TLR signaling (Taganov et al., 2006), 
we examined the possibility that miR-146a deletion might 
affect a mouse’s response to bacterial challenge. We found that 
young miR-146a–null mice systemically overproduced pro-
inflammatory cytokines like TNF, IL-6, and IL-1 in response 
to injection with a sublethal LPS dose (Fig. 2, A and B; and 
Fig. S2 A). In addition, we observed elevated serum levels of 
IL-10 in miR-146a KO animals after LPS challenge, whereas 
the levels of two other cytokines, IL-12 and IFN-, did not 
change significantly (Fig. S2, B–D). In agreement with these 
observations, miR-146a–null mice succumbed much faster to 
the effects of septic shock than their WT littermates when 
injected with a lethal LPS does (Fig. 2 C) and in the process 
exhibited signs of a hypercytokinemia (Fig. S2, F and G).
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changes (Fig. 2, G and I). Of note, expression of both 
TRAF6 and IRAK1 genes was not affected at the mRNA 
level (Fig. S2, H and I).
In contrast, THP1/146 cells expressed decreased amounts 
of IRAK1 and TRAF6 when compared with THP1/SCR 
control cells (Fig. 3 C). miR-146a had quantitatively different 
effects on target regulation in BMDMs and THP-1 cells: 
TRAF6 was derepressed more strongly than IRAK1 in 
miR-146a–null BMDMs; in contrast, miR-146a overexpres-
sion had a stronger impact on down-regulation of IRAK1 but 
not TRAF6 levels in THP-1 cells. Despite these differences, both 
of these molecular outcomes are consistent with our proposed 
model (Taganov et al., 2006), and the discrepancy in the ex-
tent of miR-146a target regulation requires further study.
transcripts in either unstimulated or LPS-stimulated cells 
(Fig. S2 J), despite significant changes in the expression of 
multiple genes in the KO cells (Tables S1 and S2).
To examine whether key miR-146a targets were de-
repressed primarily at the protein level, we have analyzed 
expression levels of several predicted molecular targets of 
miR-146a in primary miR-146a/ macrophages and in the 
THP1/146 cell line by Western blot. Consistent with our 
proposed model (Taganov et al., 2006), analysis of miR-146a–
null BMDMs revealed a marked increase in TRAF6 and 
IRAK1 protein levels in comparison with WT cells (Fig. 2, F 
and H). The derepression of TRAF6 and IRAK1 genes was 
not limited to the KO macrophages, as other hematopoietic 
tissues (e.g., peripheral B cells) also showed qualitatively similar 
Figure 2. Exaggerated inflammatory response in miR-146a–null mice. (A and B) Serum levels of TNF (A) and IL-6 (B) in miR-146a/ (n = 5; KO) 
and WT (n = 6) animals challenged intraperitoneally with sublethal dose of LPS (1 mg/kg). Peripheral blood was drawn at the times indicated in the 
graphs, and cytokine concentrations were assessed by ELISA. Results are shown as means; data are representative of two independent experiments.  
P-value calculations were performed using Student’s t test. (C) Kaplan-Meier survival curves of miR-146a/ (KO) and WT mice (n = 12 for each group) 
challenged with a lethal dose of LPS (35 mg/kg). Results are representative of two independent experiments. P-value calculation was performed using 
log-rank (Mantel-Cox) test. (D and E) Production of TNF (D) and IL-6 (E) by miR-146a/ (KO) and WT BMDMs in response to 10 ng/ml LPS challenge. Cells 
were stimulated for the indicated time, and cytokine concentrations were assessed by ELISA. Data are shown as mean ± SD. Results are representative of 
three independent experiments. (F and G) Western blot analysis of TRAF6 and IRAK1 protein expression in WT and miR-146a/ (KO) BMDMs (F) and 
CD19+ splenic B cells (G). Numbers under the blots denote relative expression normalized to -actin expression for each sample. Two mice per genotype 
were analyzed. Results are representative of two independent experiments. (H and I) Quantification of Western blots in F and G. Relative TRAF6 and IRAK1 
expression in WT and KO BMDMs (H) and CD19+ splenic B cells (I) is plotted. Data from two mice for each genotype were averaged and are expressed as a 
ratio of protein expression in miR-146a KO to WT cells. All experiments were carried in the B6/miR-146a/ strain of mice.
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supporting the notion of ongoing systemic inflammation in 
the KO mice (Fig. 4 F). As often observed for autoimmune 
disorders in people (Dale et al., 2006), miR-146a/ females 
were more affected by the disease than male littermates: the 
death rate in the former was significantly accelerated (Fig. S4 A). 
The onset of the immunoproliferative and autoimmune phe-
notypes was somewhat delayed in B6/miR-146a/ line, and 
the rate of premature death was lower in this background 
(Fig. S4 B). In addition, the penetrance of the autoimmune 
phenotype in both strains of miR-146a–null mice was incom-
plete, and splenomegaly in KO animals was not always ac-
companied by lymphadenopathy.
Autoimmunity in miR-146a KO mice correlates 
mechanistically with a loss of peripheral T cell tolerance
Activation of peripheral T cells in naive mice is often a sign of 
a break in immune tolerance and is commonly found in 
mouse models of autoimmune diseases, like that observed 
in miR-146a/ mice. Examination of the T cell lineage in 
miR-146a–null mice revealed that a large fraction of periph-
eral T cells (both CD8 and CD4 positive) displayed an acti-
vated, effector status: they stained positively for classical T 
cell activation markers CD69 and CD44 and negatively for 
CD62L (Fig. 4 G). Thus, it appears that lack of miR-146a 
expression over time can lead to a loss of peripheral T cell 
tolerance that correlates with the development of an auto-
immune disease in miR-146a–null mice.
Massive myeloproliferation in miR-146a KO mice
Detailed analysis of the miR-146a–null secondary lymphoid 
organs demonstrated a range of pathological phenotypes. The 
splenomegaly noted grossly was found to result mainly from 
myeloid proliferation. Analysis of hematopoietic cell lineages 
in the secondary lymphoid organs of miR-146a–null mice by 
flow cytometry revealed massive myeloproliferation (10-
fold increase in the number of CD11b+ cells), whereas no 
significant change in the absolute number of B and T cells 
was found (Fig. 5 A and Fig. S5, A and B). CD11b+GR1+ 
blasts were the major cell population of the expanding my-
eloid compartment in KO spleens (Fig. 5 B). Aging miR-146a 
KO mice displayed anemia, thrombocytopenia, and lympho-
penia (Fig. 5, C–J), as well as extramedullary erythropoiesis 
(Fig. S5 C), which are abnormalities frequently associated 
with BM failure, myelodysplastic syndrome (MDS), and 
myeloproliferative conditions. We also observed a mild and 
variable expansion of CD11b+ precursor cells in the KO BM 
(unpublished data).
miR-146a regulates myeloproliferation by controlling 
expression of M-CSF receptor
To test for a possibility that miR-146a deletion affects the 
number of myeloid precursor cells, we have performed col-
ony-forming assays using BM cells and M-CSF or G-CSF as 
differentiating agents. We found that miR-146a–deficient 
BM gives rise to a comparable number of granulocyte and 
macrophage CFUs as observed for the WT marrow (Fig. 6 A), 
In addition, LPS treatment of THP1/SCR control cells 
also resulted in repression of IRAK1 and TRAF6 protein ex-
pression (Fig. 3 C). The extent of this repression in THP1/
SCR was quantitatively very similar to the level of silencing 
of the target proteins in THP1/146 cells, suggesting that up-
regulation of miR-146a expression in THP1/SCR cells is 
mediating this effect. Degradation of IRAK1 protein in re-
sponse to LPS was shown to contribute to the establishment 
of endotoxin tolerance (Li et al., 2000), in turn suggesting a 
potential role for miR-146a in this process, as supported by a 
recent study by Nahid et al. (2009).
Aging miR-146a–null mice develop autoimmune disorder
Although gross pathology in young miR-146a–null mice was 
unremarkable, aged mutant mice began to display several 
abnormal phenotypes. Starting at 6–8 mo, many 129.B6/ 
miR-146a/ mice exhibited signs of an immunoproliferative 
disease, characterized by splenomegaly, lymphadenopathy, and 
premature death (Fig. 4, A–C). Histological examination of 
tissues from miR-146a–null mice revealed multiorgan inflam-
mation manifested by lymphocytic and monocytic infiltrates 
in various organs, including liver, kidneys, and lungs, with 
some evidence of tissue damage (Fig. 4 D and not depicted). 
These features were suggestive of autoimmune disease, and 
testing the serum of aged miR-146a–null mice for the pres-
ence of autoantibodies against double-stranded DNA revealed, 
on average, a 60-fold higher titer in KO animals compared with 
WT controls (Fig. 4 E). Moreover, aging 129.B6/miR-146a/ 
mice displayed moderately elevated serum levels of IL-6, thus 
Figure 3. Ectopic expression of miR-146a in THP-1 cells results 
in attenuation of inflammatory response. (A and B) Production of 
TNF (A) and IL-6 (B) by THP-1 stable cell lines ectopically expressing 
either miR-146a (THP1/146) or scramble control sequence (THP1/SCR) in 
response to 1 µg/ml LPS stimulation. Cells were stimulated for the indi-
cated time, and cytokines concentrations were assessed by ELISA.  
Results are shown as mean ± SD. Data are representative of two  
independent experiments. (C) Western blot analysis of TRAF6 and IRAK1 
protein expression in THP1/146 and THP1/SCR clones stimulated or not 
with LPS, as indicated. Numbers under the blots denote relative expres-
sion normalized to -actin expression for each sample. Data are repre-
sentative of two independent experiments.
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Of note, the level of CSF1R expression on BMDM cells ob-
tained from several KO BMs correlated well with the rate of 
proliferation of these cell cultures (Fig. 6, C and D), suggest-
ing that CSF1R expression might indeed underlie the differ-
ences in proliferation of these cells. Moreover, pharmacological 
inhibition of CSF1R signaling in this BMDM proliferation 
assay significantly attenuated the growth of KO macrophages 
(Fig. S6, A and B). Interestingly, CSF1R receptor is predicted 
by several computational algorithms to function as a putative 
miR-146a target because the 3 UTR of this mouse gene 
suggesting that miR-146a deletion has no effect on the rate of 
production of myeloid progenitors. Because M-CSF is known 
to act as a growth factor for myeloid cells, we have also mea-
sured the rate of proliferation of BMDMs differentiated in the 
presence of M-CSF and observed a markedly accelerated 
growth of miR-146a–null BMDMs (Fig. 6, B and C). To ex-
plain this finding, we have examined the level of cell surface 
expression of M-CSF receptor (CSF1R) on proliferating 
miR-146a–null BMDMs by FACS analysis and found it to be 
significantly elevated in comparison with WT cells (Fig. 6 D). 
Figure 4. Deletion of miR-146a in mice results in autoimmune disorder. (A) Splenomegaly and lymphadenopathy observed in miR-146a/ mice. 
Photographs of spleens and peripheral lymph nodes removed from a single representative WT and KO mouse. (B) Spleen weights observed in WT (n = 8),  
miR-146a+/ (HET; n = 3), and miR-146a/ (KO; n = 12) animals. Results are shown as means and are representative of two independent experiments.  
P-value calculation was performed using Student’s t test. (C) Kaplan-Meier survival curves of WT, miR-146a+/ (HET), and miR-146a/ (KO) mouse popula-
tions. P-value calculations were performed using log-rank (Mantel-Cox) test. P-value for WT and KO curve comparison is <0.0001. P-value for WT and HET curve 
comparison is 0.0041. (D) Multiorgan inflammation in miR-146a/ mice. Hematoxylin- and eosin-stained sections of liver and kidney from miR-146a+/+ 
(top) and miR-146a/ (middle, low magnification; bottom, high magnification) mice. Note the leukocytic infiltrates in the KO liver (circled with dashed lines), 
compared with a relatively spared portal triad (PT) in the WT liver. At higher magnification, degenerated hepatocytes (marked by arrows) displaying frag-
mented nuclei and eosinophilic cytoplasm indicate tissue damage caused by the inflammatory infiltrates. Note the large infiltrate of inflammatory cells (cir-
cled) in the miR-146a/ kidney. In the low-power image, the KO tubules appear more eosinophilic, and their lumina are dilated. At higher magnification, a 
degenerated tubule (marked by arrows) indicates tissue damage caused by the inflammatory infiltrates. Bars: (top and middle) 200 µm; (bottom) 40 µm.  
(E) ELISA-based analysis of autoantibodies against double-stranded DNA (dsDNA) in the serum of WT (n = 11) and miR-146a/ (KO; n = 17) animals. Ab, 
antibody. (F) Analysis of IL-6 levels in serum of miR-146a+/ (HET; n = 15) and miR-146a/ (KO; n = 21) animals by ELISA. (E and F) Results are shown as 
means. P-value calculation was performed using Student’s t test. (G) FACS analysis of CD4+ and CD8+ splenocytes from miR-146a+/ and miR-146a/  
animals using anti-CD62, -CD44, and -CD69 antibodies. Gray plot indicates miR-146a+/ cells, and the open plot indicates miR-146a/ cells. Data are repre-
sentative of three independent experiments. All experiments were performed using the 129.B6/miR-146a/ strain of mice.
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for these tumors. More detailed histological sampling of lym-
phoid organs in aging 129.B6/miR-146a/ mice has revealed 
four distinct temporal stages in the tumorigenesis process. The 
first manifestation of the disease in fairly young miR-146a/ 
mice is displayed as follicular hyperplasia in the spleen (Fig. S7, B 
and G). Then, at 6–9 mo, when KO mice started to develop 
splenomegaly, the histological picture became more heteroge-
neous: follicular hyperplasia remained a frequent abnormality, 
but many of the animals showed features suggestive of BM 
failure such as markedly expanded splenic hematopoiesis 
(Fig. S7, C and H). A significant proportion of disease-afflicted 
miR-146a/ mice aged 9–12 mo showed signs of low-grade 
follicular lymphoma and/or myeloproliferative disease with 
heterogeneous infiltrates in the spleen composed of lympho-
cytes and myeloid cells (Fig. S7, D, I, and K). Some cases of 
high-grade follicular lymphoma, with a preponderance of large 
cells, were also seen in mice aged around 1 yr (Fig. S7, E, J, 
and L). The transformation process accelerated after 12 mo, 
when several instances (n = 9) of high-grade large cell hemato-
lymphoid neoplasms were detected (Fig. 7, B–E). The rate of 
neoplastic lesions in aging miR-146a–null mice (20%) was sig-
nificantly higher than in WT animals (2.4%; Fig. 7 F).
contains one evolutionary conserved and one nonconserved 
binding site for miR-146a. To determine whether miR-146a 
can indeed control CSF1R expression posttranscriptionally 
through binding to its 3 UTR, we have fused the 3 UTR of 
mouse CSF1R to a luciferase gene and tested this construct 
in a 3 UTR reporter test. No significant change in Lucifer-
ase-CSF1R 3 UTR reporter expression was observed in the 
presence of an excess of miR-146a (unpublished data), sug-
gesting that miR-146a may control CSF1R expression in 
myeloid cells indirectly.
Aging miR-146a–null mice develop tumors
The premise that miR-146a can control cell proliferation/ 
differentiation was further supported by an intriguing obser-
vation in some aging (older than 1 yr) 129.B6/miR146a-null 
mice. These animals developed frank tumors in their second-
ary lymphoid organs, most frequently in their spleens (Fig. 7 A). 
Histologically, these neoplasms were characterized as diffuse 
large cell neoplasms (Fig. 7, B–E) that stained negatively with 
pan-B, -T, and -myeloid cell markers (CD19, CD3, and CD11b, 
respectively) while displaying positive immunostaining only 
with anti-CD45 antibody, indicating a hematolymphoid origin 
Figure 5. Myeloproliferation and BM failure in aging miR-146a/ mice. (A) Absolute cell counts of myeloid cells (CD11b+) in WT (n = 7),  
miR-146a+/ (HET; n = 4), and miR-146a/ (KO; n = 10) spleens. Results are shown as means and are representative of two independent experiments.  
(B) FACS analysis of myeloid cells in WT and KO spleens. Gated are Gr1 and CD11b double-positive cells. Numbers indicate percentage of cells in the gate. 
Data are representative of three independent experiments. (C–J) Complete blood count test with differential examination of peripheral blood from young 
(4 mo old; n = 6 for both genotypes) and old (14 mo old; n = 8 for both genotypes) WT and miR-146a/ (KO) mice. (C) Absolute white blood cell 
counts. (D) Absolute red blood cell counts. (E) Absolute thrombocyte counts. (F) Absolute neutrophil counts. (G) Absolute lymphocyte counts. (H) Absolute 
monocyte counts. (I) Hemoglobin concentration. (J) Blood hematocrit. (A and C–J) P-value calculations were performed using Student’s t test. Experiments 
in B–J were performed using the B6/miR-146a/ strain of mice. The experiment A was performed in 129.B6/miR-146a/ mice.
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note that the distal region of chromosome 5q, which contains 
the miR-146a gene (5q33) in man, has been previously sug-
gested to harbor susceptibility loci for autoimmune diseases 
such as rheumatoid arthritis (Tokuhiro et al., 2003), Crohn’s 
disease (Rioux et al., 2001), asthma (Kauppi et al., 2001), and 
psoriasis (Friberg et al., 2006).
We have shown that miR-146a is expressed rather widely 
in the mouse immune system, and its expression can be up-
regulated as a result of activation or maturation of myeloid 
and lymphoid cells. Therefore, mechanistically, the auto-
immune phenotype in miR-146a KO mice can be driven by 
miR-146a deficiency in several cell lineages, and we have 
provided evidence of the contribution of at least two different 
cell types to this phenotype. First, we believe that excessive 
production of proinflammatory cytokines, a well-established 
driver of or contributor to autoimmune disease, in miR-146a 
KO mice can be explained by a functional defect in tissue 
macrophages as they are often considered to be a major source 
for proinflammatory cytokines in the body. We have shown 
that stimulation of miR-146a–deficient macrophages with 
LPS results in an overproduction of TNF and IL-6 proteins; 
in contrast, monocytes with ectopic expression of miR-146a 
display a dampened inflammatory response (Perry et al., 2008; 
Nahid et al., 2009; this study). Second, we found that a major-
ity of peripheral effector T cells in miR-146a KO display an 
activated status, suggesting a breakdown in the peripheral 
T cell tolerance. Further studies will be required to test whether 
this T effector defect is cell autonomous or is actually a result 
of a defective function of regulatory T cells observed in 
miR-146a–null mice (Lu et al., 2010).
To gain further insight into the mechanism of the auto-
immune defect in miR-146a–deficient mice, we have com-
pared gene expression profiles of WT and miR-146a–deficient 
BMDMs as well as CD4+ splenic T cells (unpublished data) 
DISCUSSION
Negative regulation of the immune response plays an impor-
tant role in controlling homeostasis of the immune system 
and preventing development of autoimmune diseases. Multiple 
regulatory mechanisms including a complicated network of 
transcriptional factors and receptors as well as adapter and 
decoy molecules have evolved to keep activation of the immune 
system in check. Previously, we have proposed that miRNAs 
might constitute an integral component of a negative feedback 
mechanism in the innate immune system (Taganov et al., 
2006), and in this study, we have provided functional evi-
dence that miR-146a can serve as a key negative regulator of 
inflammation/autoimmunity.
Mice deficient in miR-146a expression are over-respon-
sive to bacterial challenge and produce excessive amounts of 
proinflammatory cytokines (TNF and IL-6) and second mes-
sengers (NO) in response to LPS. As a result, miR-146a KO 
mice are very susceptible to endotoxic shock. In addition, 
aging miR-146a–null mice die prematurely because they de-
velop a pathological condition that has the classical signs of an 
autoimmune disease: splenomegaly, lymphadenopathy, multi-
organ inflammation with tissue damage, a high titer of auto-
antibodies, and elevated levels of proinflammatory cytokines 
in the blood. Collectively, these findings strongly suggest that 
miR-146a is required for proper termination of the immune 
response, and its elimination is seriously deleterious to the 
organism. The late onset of the autoimmune phenotype in 
miR-146a KO and its incomplete penetrance suggest that the 
break of immune tolerance in these mice occurs gradually 
over time, perhaps as a result of progressive exposure to patho-
gens and/or commensal bacteria in the gut. The autoimmune 
phenotype of miR-146a–null mice raises a possibility that 
misregulation of miR-146a expression might contribute to the 
pathology of human autoimmune diseases, making it relevant to 
Figure 6. miR-146a–null BMDMs proliferate 
more robustly in response to M-CSF and express 
more CSF1R on their cell surface. (A) Analysis of 
myeloid precursor cells by colony-forming cell assays. 
BM cells from WT and miR-146a–null mice (KO) were 
grown for 10 d in methylcellulose in the presence of 
the indicated concentrations of recombinant M-CSF 
or G-CSF, and the number of macrophage and granu-
locyte CFUs was scored under a microscope. (B) Pho-
tographs of proliferating in response to 50 ng/ml 
M-CSF BMDM cultures, derived from WT and  
miR-146a/ (KO) mice. Pictures were taken on day 3 
after cell plating and are representative of several 
biological replicates. Data are representative of two 
independent experiments. (C) Quantification of cel-
lular proliferation of differentiating BMDM cultures 
from WT and miR-146a/ (KO) mice in response to 
50 ng/ml M-CSF. Three age- and gender-matched 
mice were used per genotype. Cell proliferation was 
assessed by MTS assay on day 3 after cell plating. 
Data are representative of two independent experiments. (A and C) Data are represented as mean ± SD. (D) FACS analysis of cell surface CSF1R expression 
on BMDM cells, derived from three WT and three miR-146a/ (KO) mice as described in C. Cells were pregated for CD11b and F4/80 markers first. Data 
are representative of two independent experiments. All experiments were performed using the B6/miR-146a/ strain of mice.
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repression of protein synthesis without significant destabiliza-
tion of the transcripts.
Lack of global derepression of miR-146a targets prompted 
us to examine expression levels of a few selected miR-146a 
target proteins, and we were able to observe a significant in-
crease in expression of TRAF6 and IRAK1 at the protein but 
not at the mRNA level in several KO cell lineages. These two 
adapter molecules were previously identified as putative 
miR-146a targets (Taganov et al., 2006). In contrast, overex-
pression of miR-146a in monocytes resulted in a significant 
decrease in the levels of these two signaling molecules in our 
and others’ hands (Nahid et al., 2009). Combined, these find-
ings suggest that TRAF6 and IRAK1 are indeed bona fide 
miR-146a targets, whose misregulation might very well be 
behind the autoimmunity and inflammation observed in 
miR-146a/ mice because these two genes are required for 
signal transduction by a very diverse group of immune recep-
tors, including antigen receptors, TLRs, and members of the 
IL-1 and TNF receptor families. Because these two adapter 
molecules often work together in a linear cascade, even small 
changes in their expression levels could have profound effects 
on downstream NF-B and MAPK (mitogen-activated pro-
tein kinase) signaling. Overexpression of either of these genes 
in cells was shown to lead to the activation of IKK (IB kinase) 
and MAPK pathways, resulting in overproduction of proin-
flammatory cytokines (Cao et al., 1996; Ishida et al., 1996; Li 
et al., 2001). In addition, TRAF6 has been strongly implicated 
in the development and function of multiple hematopoietic 
lineages (Choi, 2005), whereas IRAK1 deficiency makes mice 
more resistant to the onset of autoimmune diseases (Deng 
et al., 2003; Berglund et al., 2008). Further studies of mice 
carrying heterozygous alleles of either TRAF6 or IRAK1 
genes on an miR-146a–null background might be able to ad-
dress the exact contribution of each of these miR-146a targets 
to the autoimmune phenotype of miR-146a KO mice.
Our results suggest that in addition to its anti-inflamma-
tory role, miR-146a plays a negative regulatory role in the de-
velopment of myeloid cells because its deletion in mice results 
in a myeloproliferative disorder with a massive accumulation 
of Gr1+Mac1+ blast cells in the secondary lymphoid organs. 
This defect seems to result from an excessive proliferative 
capacity of myeloid cells in the absence of miR-146a caused 
by increased CSF1R expression, producing a more robust 
proliferation of myeloid cells in response to M-CSF without 
a change in the number of myeloid progenitors.
Increased CSF1R expression is strongly associated in the 
literature with myeloproliferative diseases. Up-regulation of 
CSF1R expression was noted both in human and mouse acute 
myeloid leukemia (AML; Gisselbrecht et al., 1987; Rambaldi 
et al., 1988; Wang et al., 1988). A chromosomal translocation 
resulting in expression of a fusion protein between RBM6 
(RNA-binding motif protein 6) and CSF1R was recently re-
ported to associate with AML and to cause myeloproliferative 
disorder in mice with an accumulation of Gr1+Mac1+ blasts in 
spleen and liver (Gu et al., 2007). Moreover, in the AML model 
resulting from aberrant expression of the leukemia-associated 
but did not detect a significant global derepression of miR-146a 
targets using computer algorithms, as was reported for some 
other miRNA KO models (Rodriguez et al., 2007; Baek 
et al., 2008). Our failure to observe a global change in ex-
pression of putative miR-146a targets in the tissues of KO 
mice suggests that either miR-146a regulates a rather re-
stricted set of targets, which would preclude computer al-
gorithms from detecting statistically significant enrichment, 
or that the majority of miR-146a targets are regulated by 
Figure 7. Increased rate of tumorigenesis in mice as a result of 
miR-146a ablation. (A) Photograph of spleens isolated form represen-
tative WT and miR-146a/ (KO) mice; arrows are pointing at frank 
tumors. (B–E) Hematoxylin- and eosin-stained sections of two indepen-
dent tumors isolated from miR-146a/ mice showing features of dif-
fuse large cell hematolymphoid neoplasms. The lower-power images 
show diffuse infiltrate without any architecture, whereas at higher 
magnification, the cells are very large with nuclei approaching 20 µm in 
size. Bars: (B and D) 400 µm; (C and E) 40 µm. (F) Rates of neoplasm 
occurrence in cohorts of aging miR-146a+/+ (n = 42; mean age = 537 d) 
and miR-146a/ (n = 45; mean age = 571 d) mice. P-value calculation 
was performed using two-tailed Fisher’s exact test. All experiments were 
carried with 129.B6/miR-146a/ mice.
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cancer are intimately linked (Balkwill and Mantovani, 2001; 
Coussens and Werb, 2002; Karin, 2006; Mantovani et al., 2008). 
Further research into the molecular mechanism of miR-146a 
action will be required to understand whether this miRNA truly 
serves as a bridge between the two phenomena. These efforts 
will not only provide us with a deeper understanding of inflam-
matory and cancer induction processes but also might lead to 
new means for therapeutic intervention in chronic diseases.
MATERIALS AND METHODS
Generation of miR-146a/ mice. To generate miR-146a/ mice, we 
created a targeting construct in which 295 bp of genomic sequence contain-
ing mouse pre–miR-146a were replaced with a floxed neomycin expression 
cassette. The assembly of the targeting construct was performed by recom-
bineering in bacteria according to the protocol established by Copeland et al. 
(2001). The linearized targeting construct was then electroporated into CJ7 
or Bruce4 embryonic stem cell lines to generate 129.B6/miR-146a/ or 
B6/miR-146a/ mouse strains, respectively. Neomycin-resistant clones that 
had undergone homologous recombination were identified by Southern 
blotting and further analyzed for a normal karyotype using DAPI staining. 
The resulting targeted embryonic stem clones were injected into C57BL/6 
or C57BL/6-Tyr blastocysts and transferred into pseudopregnant foster females 
to produce chimeric mice. Germline-competent chimeras were then used to 
produce heterozygous F1 litters that were crossed with C57BL/6Tg-EIIa-Cre 
mice to remove the Neo selection cassette. WT C57BL/6, C57BL/6-Tyr, and 
C57BL/6Tg-EIIa-Cre mice were obtained from the Jackson Laboratory. 
Animal experiments were approved by the Institutional Animal Care and Use 
Committees of the California Institute of Technology and Explora Biolabs.
miRNA and mRNA qRT-PCR. Total RNA was isolated using TRIZOL 
reagent (Invitrogen), the mirVana miRNA Isolation kit (Invitrogen), or the 
miRNeasy kit (QIAGEN). miRNA expression was measured with the mir-
Vana qRT-PCR miRNA Detection kit (Invitrogen) or TaqMan miRNA 
assays (Applied Biosystems) according to the vendor protocol and normalized 
by 5S rRNA, U6 small nuclear RNA (snRNA), or sno234 snRNA levels. 
Expression of TRAF6 and IRAK1 genes was analyzed by TaqMan Gene Expres-
sion assays (Applied Biosystems) and normalized by mouse -actin expression.
Cell culture and reagents. THP-1 cells were obtained from the American 
Type Culture Collection and cultured in RPMI medium 1640 supplemented 
with 10% FBS, 1× nonessential amino acids, 100 U/ml penicillin, 100 U/ml 
streptomycin, and 2 mM glutamine in a humidified incubator containing 5% 
CO2 at 37°C. BMDMs were differentiated from BM precursors in the pres-
ence of 50 ng/ml recombinant mouse M-CSF (PeproTech) according to 
protocol (Karincaoglu et al., 2003). BM-derived plasmacytoid dendritic cells 
were differentiated from BM cells by culturing in the presence of 100 ng/ml 
recombinant Flt3 protein for 8–10 d. B220+ dendritic cells were then sorted 
out using Miltenyi Biotech MicroBeads and stimulated with 5 μg/ml CpG 
for 24 h. LPS (Escherichia coli 055:B5) was obtained from Sigma-Aldrich.
Western blot. Total protein extracts were resolved on 10% Bis-Tris 
NuPAGE gel, transferred on nitrocellulose membrane, and blotted for the 
protein of interest. Anti–mouse IRAK1 antibodies were obtained from Cell 
Signaling Technology, and anti-mouse TRAF6 were obtained from MBL 
International; anti–human IRAK1 and TRAF6 were purchased from Santa 
Cruz Biotechnology, Inc. Quantification of relative expression for each target 
protein was performed in Photoshop CS4 (Adobe), and -actin levels were 
used for normalization.
Northern blot. Northern blot analysis was performed as described previ-
ously (Taganov et al., 2006). Membranes were hybridized with -32P–labeled 
DNA oligonucleotide probes that were perfectly complementary to mature 
miR-146a or sno234.
MOZ (monocytic leukemia zinc finger)-TIF2 fusion protein, 
a high level of CSF1R expression was shown to confer 
leukemia-initiating activity to myeloid cells (Aikawa et al., 2010). 
Despite the fact that miR-146a was predicted to target the 
CSF1R gene by multiple miRNA target prediction algo-
rithms, we failed to detect direct interaction between miR-146a 
and the 3 UTR of the CSF1R gene, suggesting that up- 
regulation of CSF1R expression on macrophage precursors 
in miR-146a–null mice may be mediated by an intermediate 
factor. Several putative miR-146a targets with an established 
role in myeloproliferation disease (e.g., RUNX1T1, CBFA2T2, 
SPI1, etc.) could potentially serve such a role.
Misregulation of TRAF6 gene expression also can con-
tribute to the myeloproliferative phenotype of miR-146a–null 
mice because this gene was shown to play an important role 
in the development of myeloid cells, e.g., osteoclasts and den-
dritic cells (Lomaga et al., 1999; Naito et al., 1999; Kobayashi 
et al., 2003). Moreover, chimeric mice overexpressing TRAF6 
in the hematopoietic compartment were shown to develop 
either BM failure or AML starting at 5 mo after BM trans-
plantation (Starczynowski et al., 2010).
It is worth noting that the loss of human chromosome 5 
or deletion of the 5q region, which harbors the miR-146a 
gene, is associated with MDS and AML (Thirman and Larson, 
1996). Recently, abrogation of miR-146a expression with 
consequent up-regulation of TRAF6 expression was strongly 
implicated in the pathogenesis of MDS (Starczynowski et al., 
2010). Although miR-146a–null mice in our examination 
lack some of the classical features of 5q syndrome (like neu-
tropenia, thrombocytosis, and megakaryocytic dysplasia), future 
analysis of the heterozygous mice will be required to establish 
the exact contribution of miR-146a to this syndrome. In ad-
dition, two other miRNAs, miR-155 and miR-223, have also 
been implicated in the development of myeloid cells in mice 
(Johnnidis et al., 2008; O’Connell et al., 2008). Interestingly, 
miR-155, which, like miR-146a, can also be induced by LPS, 
was shown to cause myeloproliferation, albeit it was over-
expression and not deletion that led to the hyperplasia of 
myeloid cells.
Our data also imply that miR-146a can function as a 
tumor suppressor gene, because aging miR-146a–null mice 
develop frank tumors in lymphoid organs. This conclusion is 
in agreement with previous studies, suggesting that inhibition 
of miR-146a activity could promote tumor growth and metas-
tasis (Bhaumik et al., 2008; Lin et al., 2008; Hurst et al., 2009; 
Xia et al., 2009). In addition, down-regulation of miR-146a 
expression by the c-Myc oncogenic transcription factor was 
previously observed in human and mouse B cell lymphomas 
(Chang et al., 2008). However, the observed latency to develop-
ment of these tumors clearly suggests that loss of miR-146a alone 
is insufficient for definitive tumorigenesis and that there are 
other factors that likely collaborate in the development of frankly 
malignant tumors. Excessive inflammation/autoimmunity seen 
in miR-146a KO mice can potentially serve as a confounding 
factor in the development of neoplasms in these animals. 
A growing body of evidence suggests that inflammation and 
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Complete blood cell count tests. Complete blood cell count tests with 
differential examination were performed by MDS Pharma Services.
In vivo LPS challenges. For sublethal LPS challenge, mice were injected 
intraperitoneally with 1 mg/kg LPS. Peripheral blood was collected before 
the LPS injection as well as at 2 and 24 h after injection by retro-orbital 
bleeding. For lethal LPS challenge, mice were injected intraperitoneally with 
35 mg/kg LPS and then monitored for 72 h. Moribund animals were eutha-
nized immediately.
Tumor experiments. Cohorts of aging (65–106 wk old) 129.B6/ 
miR-146a/ (n = 45) and WT (n = 42) animals were sacrificed and exam-
ined for the presence of gross abnormalities. Organs with apparent tumor 
growth as well as enlarged spleens/lymph nodes were collected and submit-
ted for histological analysis.
Statistical tests. All statistical analyses were performed using Excel (Micro-
soft) or Prism 5 (GraphPad Software) software. For animal survival curves, 
p-value was calculated using the Mantel-Cox log-rank test; for all other data, 
the Student’s two-tailed t test was used. Statistical analysis of neoplasm occur-
rence was performed using the two-tailed Fisher’s exact test.
Online supplemental material. Fig. S1 describes the generation of 
miR-146a–null mice. Fig. S2 shows ELISA analyses of cytokine expression 
in the serum of LPS-stimulated miR-146a–null mice and qRT-PCR and 
Sylamer analysis of gene expression in miR-146a–null BMDMs. Fig. S3 de-
scribes the generation of THP1/146 and THP1/SCR cells and analysis of 
IL-12 secretion in these cells in response to LPS. Fig. S4 shows Kaplan-Meier 
survival curves for males and females from the 129.B6/miR-146a/ line, as 
well as lifespan for the B6/miR-146a/ line. Fig. S5 shows absolute T and 
B cells counts, as well as extramedullary hematopoiesis in miR-146a–null 
spleens. Fig. S6 shows that pharmacological inhibition of CSF1R activity 
blocks BMDM proliferation. Fig. S7 shows the characterization of tumori-
genesis stages in miR-146a–null mice. Table S1, included as an Excel file, lists 
genes that are differentially expressed in miR-146a–deficient BMDMs. Table 
S2, included as an Excel file, lists genes that are differentially expressed in 
LPS-treated miR-146a–deficient BMDMs. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20101823/DC1.
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Flow cytometry. Single cell suspensions prepared from various mouse 
hematolymphoid tissues were treated with red blood cell lysis buffer (BioLe-
gend) and then stained with fluorophore-conjugated monoclonal antibodies 
against specific cell surface markers (eBioscience). Stained cells were assayed 
using a FACSCalibur flow cytometer (BD) and analyzed with FlowJo soft-
ware (Tree Star).
ELISA. For detection of cytokine levels in tissue culture media, ELISAs 
using specific combinations of capture and detection antibodies (eBioscience) 
were performed. Cytokine levels in the serum of LPS-challenged mice were 
assayed by a mouse proinflammatory 7-plex-panel kit (Meso Scale Discovery). 
Titers of autoantibodies against double-stranded DNA were calculated using 
a commercial ELISA test (BioVendor) according to manufacturer’s protocol.
Plasmid construction and generation of THP1/SCR and THP1/146 
stable cell lines. To create miR-146a expression vector, we modified FUW 
vector (Lois et al., 2002) by inserting the EGFP gene downstream of the 
ubiquitin promoter as well as puromycin resistance cassette; the cassette for 
miRNA expression was then cloned immediately downstream of the EGFP 
gene. The miRNA expression cassette was based on mouse miR-155 precur-
sor sequence, in which mature miR-155 sequence was replaced with miR-146a 
or scrambled sequences. To produce viral particles, HEK293T cells were 
transfected with lentiviral expression vectors along with helper plasmids. 
Supernatant containing virus was used to infect THP-1 cells. Stable clones of 
transduced THP-1 cells were selected in the presence of puromycin for 14 d. 
Cells from resulting puromycin-resistant colonies were pooled and desig-
nated as THP1/SCR and THP1/146 lines.
Colony-forming cell assays. Colony-forming cell assays were setup in 
MBM (methylcellulose base medium; R&D Systems) according to the man-
ufacturer’s protocol. In brief, 5 × 104 BM cells from three age- and gender-
matched WT and KO mice were plated in MBM in the presence of various 
concentrations of recombinant M-CSF and G-CSF proteins. Macrophage 
and granulocyte CFUs were scored after 10 d under a microscope (Diaphot 
200; Nikon). Assays were performed in duplicate.
BMDM proliferation assays. BM cells from three age- and gender-
matched WT and KO mice were plated at a concentration of 2 × 104 per well 
in a 96-well plate in the presence of 50 ng/ml M-CSF. 3 d later, proliferation was 
assayed using MTS reagent (Promega) according to the manufacturer’s pro-
tocol. Assays were performed in triplicates. For pharmacological inhibition of 
BMDM proliferation with CSF1R inhibitor, the experiment was repeated in 
the presence of 500 nM cFMS receptor tyrosine kinase inhibitor (EMD). The 
rate of cellular proliferation was assessed on day 4 using MTS reagent.
3 UTR reporter assays. Genomic DNA fragment (608 bp) corresponding 
to the mouse 3 UTR of CSF1R mRNA was obtained by PCR and cloned 
into pMIR-Report vector (Applied Biosystems). Site-directed mutagenesis 
was used to mutate both miR-146a binding sequences in the CSF1R 3 UTR. 
To perform an assay, 6 × 104 293FT (Invitrogen) cells were plated in a 24-
well culture dish and transfected using Attractene reagent (QIAGEN) with 
200 ng miR-146a expression plasmid or empty vector, 20 ng 3 UTR luciferase 
reporter plasmid, and 10 ng Renilla luciferase reporter plasmid (pRL-SV40; 
Promega). 48 h later, cell lysates were prepared, and the luciferase activities 
were measured using a Dual Luciferase Reporter assay system (Promega).
Morphological assessment of hematolymphoid tissues. For histo-
logical sectioning, organs were placed into 10% neutral-buffered formalin 
immediately after necropsy, fixed for 12–18 h, washed, and transferred to 70% 
ethanol before standard paraffin embedding, sectioning, and staining with 
hematoxylin and eosin. All cytological preparations were air-dried and 
stained with Wright’s stain. Both histological and cytological preparations 
were examined on a microscope (BX-51; Olympus) and photographed using 
a color charge-coupled device digital camera (Insight 4 MP; SPOT) and 
software (SPOT).
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